Healthcare Industry News: LifeScan
News Release - December 19, 2007
Ex-Hypoguard CEO to Lead WaveSense(TM) Sales and MarketingSALEM, N.H., Dec 19 (HSMN NewsFeed) -- The makers of the WaveSense(TM) line of blood glucose monitoring (BGM) products for the diabetes market (AgaMatrix) announced today that David Conn has joined the company as its Chief Commercial Officer to lead worldwide sales and marketing activities.
Conn has over 25 years of experience in the diabetes market, most notably as President and CEO of Hypoguard until its acquisition by Arkray, Inc. in 2006. Conn grew Hypoguard from $5M to $70M in annual sales and launched five new BGM systems, turning, Hypoguard into a leading BGM company. He also created significant distribution and supply relationships worldwide and captured nearly 40% of the US long term care market. Prior to Hypoguard, Conn was the Vice President of Consumer Sales, Marketing and Customer Service at J&J LifeScan, makers of the OneTouch® line of BGM products, where he was responsible for $720M in revenue. Conn has also held various sales and marketing positions with Schering-Plough HealthCare and Procter & Gamble.
"The WaveSense story is truly extraordinary with their explosive growth and remarkable technology platform. This platform has enabled the company to grow very quickly without taking on equity investment from commercial partners. I am very excited to be a part of the opportunity to expand WaveSense commercial efforts to provide more accurate and innovative products to the diabetes community," said Conn. "I am confident that WaveSense will soon be recognized as synonymous with accuracy by the home healthcare industry."
Sonny Vu, Co-Founder, Chairman and Executive Vice President will focus on new business development and product strategy. "Dave is one of the top executives in the industry and we're honored that he has joined the WaveSense team. His experience speaks for itself."
Leading diabetes educators have been advocating for more accurate BGM's and the American Diabetes Association (ADA) has been actively endorsing more stringent accuracy requirements for the last 20 years. In several clinical studies, WaveSense-enabled meters have been shown to provide results nearly twice as accurate as the major industry standards.
"As a diabetes educator, I'm on the front line of diabetes care and know that meter accuracy is a major problem," said Donna Rice, a leading diabetes educator with over 20 years of experience and President of the American Association of Diabetes Educators. "Getting an accurate glucose number is very important to the management of diabetes, especially for those who use insulin since they need a good number to dose accurately. Increased accuracy of new meters represents the next real leap in technology. I'm encouraged that diabetes patients worldwide can choose from a growing line of new meters for tighter control of their diabetes.
WaveSense is a line of diabetes products designed to improve the quality of diabetes care. Powered by a suite of patented next-generation biosensor technologies, WaveSense blood glucose monitoring systems are able to provide highly accurate results to help users better manage their diabetes. Zero- Click(TM), the WaveSense diabetes data management system, was designed to simplify data download. WaveSense and Zero-Click consist of four FDA-cleared products and are protected by a suite of more than 160 patents worldwide. For more information on or to buy WaveSense products, see www.wavesense.info .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.